USA - NASDAQ:UPC - KYG9442G1385 - Common Stock
Overall UPC gets a fundamental rating of 3 out of 10. We evaluated UPC against 192 industry peers in the Pharmaceuticals industry. UPC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UPC is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.97% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 5.65% | ||
| GM | 30.41% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.38 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.62 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.03 | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5
-0.18 (-3.55%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.03 | ||
| Fwd PE | N/A | ||
| P/S | 0.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.05 | ||
| P/tB | 0.05 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 5.65% | ||
| GM | 30.41% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 82.09% | ||
| Cap/Sales | 2.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 0.38 |
ChartMill assigns a fundamental rating of 3 / 10 to UPC.
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSE PHARMACEUTICALS INC (UPC). This can be considered as Overvalued.
UNIVERSE PHARMACEUTICALS INC (UPC) has a profitability rating of 3 / 10.
The Price/Earnings (PE) ratio for UNIVERSE PHARMACEUTICALS INC (UPC) is 0.03 and the Price/Book (PB) ratio is 0.05.